Assignee
NEOVACS
US·17 granted patents·5 pending applications·171 citations·filing 1992–2024
Top patents by PatentIndex Score
22 records- 0187US6200575B1Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising themNEOVACS·Filed 2000·Granted Mar 13, 2001·18 cites·28 claims
- 0284US7314629B2Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virusNEOVACS·Filed 2003·Granted Jan 1, 2008·15 cites·24 claims
- 0384US7022482B2Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal usesNEOVACS·Filed 2003·Granted Apr 4, 2006·14 cites·15 claims
- 0481US6093405AInactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokinesNEOVACS·Filed 1992·Granted Jul 25, 2000·55 cites·12 claims
- 0578US6878370B1Chemically modified TNF-αNEOVACS·Filed 2000·Granted Apr 12, 2005·7 cites·7 claims
- 0677US7022326B1Carboxymethylated retroviral regulatory proteins and interferon-αNEOVACS·Filed 2000·Granted Apr 4, 2006·9 cites·10 claims
- 0772US7887811B2Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier proteinNEOVACS·Filed 2006·Granted Feb 15, 2011·2 cites·16 claims
- 0869US6132721ANon-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing sameNEOVACS·Filed 1996·Granted Oct 17, 2000·20 cites·27 claims
- 0962US7351554B2Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA'sNEOVACS·Filed 2005·Granted Apr 1, 2008·0 cites·12 claims
- 1062US6455045B1Immunogenic compounds with in particular an anti-cytokine effect, preparation process, pharmaceutical compositions and kits containing themNEOVACS·Filed 1999·Granted Sep 24, 2002·13 cites·11 claims
- 1162US2025025541A1Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activityNEOVACS·Filed 2024·Application pending·0 cites
- 1261US6420141B1Anti-HIV immunogens (toxoids), preparation methods and use for preventing and treating aidsNEOVACS·Filed 1998·Granted Jul 16, 2002·17 cites·15 claims
- 1357US2025312427A1mRNA VACCINES COMPRISING IL-4 AND/OR IL-13 RNA AND USES THEREOFNEOVACS·Filed 2022·Application pending·0 cites
- 1456US7504479B2Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal usesNEOVACS·Filed 2005·Granted Mar 17, 2009·0 cites·14 claims
- 1555US12059457B2Immunogenic product comprising IL-4 and/or IL-13 for treating disorders associated with aberrant IL-4 and/or IL 13 expression or activityNEOVACS·Filed 2019·Granted Aug 13, 2024·0 cites·8 claims
- 1653US8372388B2Method for preparing a stable TNF-α vaccineNEOVACS·Filed 2005·Granted Feb 12, 2013·0 cites·20 claims
- 1753US7015016B2Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA'sNEOVACS·Filed 2000·Granted Mar 21, 2006·0 cites·6 claims
- 1851US7972603B2Stable immunogenic product comprising antigenic heterocomplexesNEOVACS·Filed 2003·Granted Jul 5, 2011·0 cites·12 claims
- 1945US2006252075A1Method for monitoring anti-HIV treatment in HIV infected individualsNEOVACS·Filed 2006·Application pending·0 cites
- 2043US2023364232A1IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERSNEOVACS·Filed 2021·Application pending·0 cites
- 2141US2018207288A1Method for treating ifnalpha related conditionsNEOVACS·Filed 2018·Application pending·0 cites
- 2223US6228890B1Use of alicyclic diamines as immunomodulatorsNEOVACS·Filed 1996·Granted May 8, 2001·1 cites·14 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →